Cosmetic

Global Vitamin B3-B4 Market Analysis Report 2023-2029 Featuring Lonza, Aurorium, Brother Enterprises, Jubilant Ingrevia, Eastman Chemical, Lasons, Glanbia, and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

The "Global Vitamin B3-B4 Market (2023 Edition): Analysis By Vitamin Type (Vitamin B3, Vitamin B4), Formulation (Dry, Liquid), By Application, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vitamin B3-B4 Market (2023 Edition): Analysis By Vitamin Type (Vitamin B3, Vitamin B4), Formulation (Dry, Liquid), By Application, By Region, By Country: Market Insights and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.
  • Emerging trends and growth opportunities in the global Vitamin B3-B4 market are thoroughly examined in the latest research.
  • The report delves into the intricacies of the market during the forecast period of 2024-2029, shining a light on critical market dynamics.
  • These insights offer key stakeholders, business leaders, and other interested parties a strategic edge in the evolving global Vitamin B3-B4 market.

Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting

Retrieved on: 
Wednesday, February 21, 2024

Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24.

Key Points: 
  • Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24.
  • “Apyx Medical is pleased to see Renuvion featured in a variety of insightful educational presentations during AACS 2024, which we believe will help to expand the awareness of our Helium Plasma Technology and its benefits,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical.
  • Demographic, procedure and safety data were collected and evaluated from a contiguous series of more than 450 patients, including 229 patients treated with Renuvion and 236 patients treated with Bipolar RF.
  • The researchers analyzed adverse events recorded by the body area during or post-procedure for each group.

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Thursday, February 29, 2024

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.

Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER

Retrieved on: 
Thursday, February 29, 2024

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER. The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.

Key Points: 
  • DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed U.S. Department of Justice ("DOJ") investigations of EHSI and other Company subsidiaries related to certain legacy marketing of Opana® ER.
  • The Company voluntarily stopped marketing Opana® ER directly to U.S. healthcare providers in 2016 and stopped selling Opana® ER in 2017.
  • EHSI also agreed to resolve the DOJ's civil investigation of the sales and marketing of Opana® ER.
  • Endo submitted the DOJ resolutions to the Bankruptcy Court for approval, which Endo is seeking in conjunction with its proposed Plan of Reorganization.

Dr. Husam Almunajed Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Husam Almunajed is a highly skilled cosmetic and restorative dentist who has made a name for himself in creating beautiful and healthy smiles for his patients. With an undergraduate degree from Villanova University and a master's degree from Georgetown University, Dr. Almunajed continued his education at the University of Connecticut School of Dental Medicine, where he completed his dental degree and a 2-year residency focused on comprehensive dental care.

Key Points: 
  • Smile Expert from New York, Dr. Husam Almunajed, continues his partnership with Haute Beauty Network, now in his sixth year.
  • "With over 20 years of experience, Dr. Almunajed founded Empire Dental Aesthetics, a state-of-the-art practice located in Manhattan, New York, specializing in cosmetic and comprehensive dentistry."
  • With over 20 years of experience, Dr. Almunajed founded Empire Dental Aesthetics, a state-of-the-art practice located in Manhattan, New York, specializing in cosmetic and comprehensive dentistry.
  • As he continues to teach and mentor the next generation of dentists, Dr. Almunajed's legacy of excellence in dentistry will undoubtedly continue to grow.

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

Retrieved on: 
Tuesday, January 23, 2024

IRVINE, Calif., Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve months affirmed Allē's position as the leading aesthetics loyalty rewards program in the country, with a ninety-two percent satisfaction rate reported by survey respondents1*.

Key Points: 
  • IRVINE, Calif., Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program.
  • From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program in the category.
  • That's why Allē is the first and only aesthetics loyalty rewards program to give its users points on more than 40 brands, products, and treatments at their Allē provider—even those that are not Allē brands.
  • For providers looking to engage with Allē for Business, please contact your local Allergan Aesthetics Business Development Manager.

PDO Max Instrumental in Lobbying for New Ruling Allowing Massachusetts Nurses to Include Polydioxanone (PDO) Thread Procedures in Scope of Practice

Retrieved on: 
Tuesday, January 16, 2024

Prior to passing the revision, on January 11, 2024, nurses in the state could not perform PDO thread procedures.

Key Points: 
  • Prior to passing the revision, on January 11, 2024, nurses in the state could not perform PDO thread procedures.
  • PDO thread procedures are a nonsurgical option for patients who desire a quick and less invasive alternative for skin rejuvenation.
  • "I believe all qualified providers should be able to practice within their skill level," PDO Max Founder and CEO Giovanna McCarthy says.
  • "Every time I see a nurse legally perform PDO thread procedures, I can say we contributed and stood up for this change."

Vitenas Cosmetic Surgery in Houston, TX Announces Cutting-Edge Technology and Its Accredited Houston Surgery Center

Retrieved on: 
Monday, January 8, 2024

HOUSTON, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Leading Cosmetic Surgery and Skincare by Dr. Paul Vitenas in Houston

Key Points: 
  • Vitenas Cosmetic Surgery announces comprehensive skincare and state-of-the-art cosmetic surgery for patients in Houston, Texas.
  • HOUSTON, Jan. 8, 2024 /PRNewswire-PRWeb/ -- Leading Cosmetic Surgery and Skincare by Dr. Paul Vitenas in Houston
    Vitenas Cosmetic Surgery focuses on providing patients with the highest standards of cosmetic surgery and skincare.
  • The center is home to the Houston Surgery Center , a fully accredited ambulatory surgical care facility designed by Dr. Vitenas himself.
  • The center is dedicated to Vitenas Cosmetic Surgery patients and gives them privacy, convenience, and a focus on safety.

STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference   

Retrieved on: 
Monday, January 8, 2024

The poster highlights the safety and efficacy of one treatment session using STRATA’s TheraClear®X technology for cystic and papular acne reduction.

Key Points: 
  • The poster highlights the safety and efficacy of one treatment session using STRATA’s TheraClear®X technology for cystic and papular acne reduction.
  • Majority of lesions demonstrated ≥50% clearing by 1-2 weeks, exceeding the criteria of ≥30% reduction in lesion size at two follow-up visits.
  • At 1-2 weeks, the most frequently reported event was mild hyperpigmentation; erythema, edema, and flaking were observed in ≤10% of lesions.
  • “The TheraClear®X Photopneumatic acne system used with the additional needle insert is a very effective and safe treatment for both cystic and pustular acne lesions.

Cosmetic Executive Women (CEW) Appoints Agnes Chapski as EVP, Business Strategy and Growth Officer

Retrieved on: 
Thursday, January 4, 2024

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Cosmetic Executive Women, Inc. (CEW), the premier organization for beauty industry professionals, announces the appointment of Agnes Chapski as the new Executive Vice President, Business Strategy and Growth Officer.

Key Points: 
  • NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Cosmetic Executive Women, Inc. (CEW), the premier organization for beauty industry professionals, announces the appointment of Agnes Chapski as the new Executive Vice President, Business Strategy and Growth Officer.
  • Agnes has a proven track record in driving transformative initiatives and brings a wealth of expertise in business strategy and growth.
  • In her new role, Agnes will be leading the development and execution of innovative strategies to fortify CEW's market position and drive growth.
  • "We are thrilled to welcome Agnes Chapski to our executive team," said President, Carlotta Jacobson.